Zimmer Biomet — Apr 28, 2026 release

Page 3 of 19   Financial Guidance The Company is updating its full-year 2026 financial guidance as follows: Projected Year Ending December 31, 2026     Previous Guidance Updated Guidance 2026 Reported Revenue Change 2.5% - 4.5% 2.5% - 4.5% Foreign Currency Exchange Impact +0.5% +0.5% 2026 Constant Currency Revenue Change 2.0% - 4.0% 2.0% - 4.0% 2026 Organic Constant Currency Revenue Change (1) 1.0% - 3.0% 1.0% - 3.0% Adjusted Diluted EPS (2) $8.30 - $8.45 $8.40 - $8.55   (1) Excludes the projected impact of the Paragon 28 acquisition through the one-year anniversary of the acquisition date, which is estimated to be approximately 100bps. (2) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure. Conference Call The Company will conduct its first quarter 2026 investor conference call today, April 28, 2026, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient e